Question Bank › Conversion calendar in hand

Conversion calendar in hand

Conversion calendar in hand: management narrates the coming year as dated deliveries of business already secured

Calls Tested
443
Answered YES
6
Hit Rate
1.4%
rare by design

OPKO Health, Inc. (OPK) — this company's answers

NO on the Q1 2022 call 2022-05-09 D
The model's full reasoning — Q1 2022 call → NOThe question asks whether management lays out a timetable of specific conversions—identified pieces of business already secured or in motion, each with timing attached—so the forward story reads as a schedule of things turning on. Let me examine the transcript for what management says about the next four or so quarters. Key items mentioned: 1. ModeX acquisition - closed today, but this is an acquisition, not a revenue-generating conversion with a timetable. They mention R&D expenses will increase as programs move to clinic over next 18 months, but no revenue timetable. 2. Pfizer milestones - $85 million in milestones from Japan and Germany launches, received in Q2. This is a one-time payment, not a recurring conversion. 3. Somatrogon gross profit share - Japan region starts in Q2 once pricing established; Europe needs two more major markets, projected about a year from initial approvals. This is somewhat vague. 4. Sema4/GeneDx - closed April 29, but this is a divestiture, not a revenue source. 5. BioReference - COVID testing volumes, Scarlet Health, Teladoc relationship, MVP Healthcare collaboration. These are described as ongoing business activities, not scheduled conversions with timing. 6. RAYALDEE - mentioned revenue but no forward timetable. The question asks about "specific conversions—identified pieces of business that are ALREADY SECURED OR ALREADY IN MOTION, each attached to an at-least-approximate time frame in which it starts contributing." Looking at what management actually says: - The $85 million Pfizer milestone is secured and will be received in Q2. That's a one-time event, not a recurring conversion. - The gross profit share from Japan starts in Q2, but they say "we have not forecasted royalty or gross profit share amounts until we develop some actual history throughout 2022." So they're not even forecasting it. - Europe gross profit share is "about a year from initial approvals" - vague and contingent on pricing in additional markets. - ModeX programs are in early development, no revenue timetable. - BioReference activities are ongoing business, not scheduled conversions. The forward guidance is mostly about testing volume assumptions (3-3.5 million COVID tests), cost reductions, and commercial investments. There's no clear timetable of secured business converting to revenue.

← Back to the full OPK analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, when management talks about the company's NEXT FOUR OR SO QUARTERS, does it lay out a TIMETABLE OF SPECIFIC CONVERSIONS \u2014 identified pieces of business that are ALREADY SECURED OR ALREADY IN MOTION, each attached to an at-least-approximate time frame in which it starts contributing \u2014 so that the forward story reads as a schedule of things turning on, rather than as hopes about demand?\n\nAnswer YES when management's own words convey BOTH of the following as one coherent forward account, in whatever form fits the business:\n\n(1) THE ITEMS ON THE TIMETABLE ARE ALREADY REAL. Management identifies concrete business whose existence is no longer in question \u2014 already won, signed, awarded, ordered, booked, contracted, built, launched, closed, or already ramping \u2014 in whatever form fits the industry: contracted work or orders scheduled for delivery; a facility, capacity, product, service, or location recently completed or opening on a stated timetable and now filling; customers or programs already signed that go live or scale on a described schedule; an acquisition or expansion already closed whose contribution phases in; committed volumes stepping up on agreed dates. One substantial item or several smaller ones together both count. Items still being pursued, negotiated, piloted without commitment, or awaiting approvals, financing, or customer decisions do NOT count toward the timetable.\n\n(2) MANAGEMENT ATTACHES TIMING AND TREATS THE SCHEDULE AS THE FORWARD STORY. Management gives each identified item an at-least-rough time anchor within roughly the coming year (this quarter, next quarter, by mid-year, second half, a named month or season) and presents working through this sequence \u2014 starting, ramping, delivering, onboarding, filling \u2014 as the main driver of where the company's results go from here, conveying directly or plainly in substance that the period just reported does not yet meaningfully reflect these contributions, so today's numbers describe the company before the scheduled conversions land.\n\nAnswer NO if the forward discussion rests mainly on demand strength, market conditions, pipeline, opportunities being pursued, or general optimism, with no dated schedule of secured items. NO if the timetable consists of routine, ordinary-course activity at the company's usual scale \u2014 the normal cadence of openings, orders, or seasonal work it always has \u2014 that management does not present as stepping the company beyond its current level. NO if the named items are contingent on approvals, financing, negotiations, or decisions not yet made, or if the only timing given is vague ('over time', 'in the coming years', 'eventually'). NO if the scheduled items' contributions are already substantially reflected in the reported results. NO if management is chiefly explaining delays, slippage, cancellations, or problems with a previously described schedule. NO if the schedule is assembled only in an analyst's question or model that management does not itself adopt.\n\nUse only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
ESEA Euroseas Ltd. Q4 2022 2023-02-15 C+
SOL ReneSola Ltd Q3 2022 2022-12-01 C+
FLL Full House Resorts, Inc. Q3 2022 2022-11-07 B
FAT FAT Brands Inc. Q4 2021 2022-03-21 F
CPK Chesapeake Utilities Corporation Q3 2017 2017-11-10 A
ESE ESCO Technologies Inc. Q2 2016 2016-05-03 A

How the model reasoned

CPK · Q3 2017 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured business and approximate time frames.
SOL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.
FLL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.

More from the question bank

Betting on a customer they cannot yet nameGround-level proof points accumulatingWinning more per swing than they used to — aFresh order-of-magnitude reference changeThis quarter could not have been described lOutside actors already movingAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.